Charter Medical, Ipratech, and APIcells to Collaborate on a Fully Automated Perfusion Platform

company logo

MANCHESTER, Conn., Sept. 16, 2013 (GLOBE NEWSWIRE) -- Charter Medical, Ltd., a division of Lydall, Inc. (NYSE:LDL), announced today that it will be collaborating with Ipratech SA and APIcells, Inc. by combining their respective expertise in single-use technology, upstream process engineering, and instrumentation control. Through this collaboration, the companies will provide customers with turnkey, fully automated, scale-free perfusion platform solutions for disposable and classical bioreactors.

As part of this collaboration, Charter Medical will be the exclusive global distributor of the portfolio that includes CYTOSYS and CYTOPERF technologies. CYTOSYS is a fully remote control system designed for real-time control and monitoring of batch, fed-batch, and continuous cell culture processes. The CYTOPERF technology is the first commercial, fully disposable cell retention device to address high-density perfusion processes.

Additionally, Charter Medical, Ipratech, and APIcells will be collaborating on the development of a continuous cell cultivation platform. The aim of the relationship is to provide customers with innovative solutions for continuous manufacturing in response to strong market demand. Dale Barnhart, President and CEO of Lydall, said, "We are very excited about this opportunity as it complements our existing portfolio and allows us to continue to better serve our customers." Mr. Barnhart further noted that, "This collaboration demonstrates Charter Medical's commitment to be a complete solution provider to the bio-processing industry."

Olivier Berteau, CEO of APIcells; and David Sergeant, CEO of Ipratech commented, "Collaborating with Charter Medical best complements our technological vision and, from a strategic perspective, allows us to most optimally address market demand."

Lydall, Inc. is a New York Stock Exchange listed company, headquartered in Manchester, Connecticut. The Company, with operations in the U.S., France, and Germany and offices in Europe and Asia, focuses on specialty engineered products for the thermal/acoustical and filtration/separation markets. Charter Medical, Ltd., a Lydall subsidiary, is a vital fluids management company focused on providing products to separate, contain and transport vital fluids in the blood and cell therapy market and the biotech and pharmaceutical industries. Lydall® is a registered trademark of Lydall, Inc. in the U.S. and other countries. All product names are trademarks of Lydall, Inc. or Charter Medical, Ltd.

CONTACT: David D. Glenn Director of Business Development and Investor Relations Telephone 860-646-1233 Facsimile 860-646-4917

Source:Lydall, Inc.